Zymeworks Inc. (ZYME)
Summary
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval
Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME's near-term upside hinges on commercial execution, label expansions, and integrating durable cash-flow assets like YUPELRI from the pending Theravance acquisition.
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to earnings of $0.03 per share a year ago.
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma
Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue beyond oncology, enhancing earnings visibility.
Zymeworks Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 80 | $1,285.47 | $1,880 | $594.53 | 46.25% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 32,052 | $745,529.52 | $754,504.08 | $8,974.56 | 1.2% |
| NA Nizar Araji National Bank Of Canada /FI/ | 1,181 | $12,680.18 | $27,800.74 | $15,120.56 | 119.25% |
| BG Bart Gancher Intech Investment Management LLC | 11,935 | $196,380.87 | $280,949.9 | $84,569.03 | 43.06% |
 Joseph Castro Nuveen LLC | 119,389 | $2.68M | $2.88M | $201,512.61 | 7.51% |
Zymeworks Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| EFV Eva Fortea Verdejo Wells Fargo | 1,236 | $29,288.18 | $29,045.93 | -$242.25 | -0.83% |
| GR Gregory Renza Truist Securities | 138.28 | $3,694.91 | $3,126.57 | -$568.34 | -15.38% |
 Yigal Nochomovitz Citigroup | 207.49 | $6,080.38 | $6,102.16 | $21.78 | 0.36% |
Zymeworks Inc. (ZYME) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Zymeworks Inc. ever had a stock split?
Zymeworks Inc. Profile
| Biotechnology Industry | Healthcare Sector | Kenneth H. Galbraith CEO | NASDAQ (NGS) Exchange | 98985Y108 CUSIP |
| US Country | 231 Employees | - Last Dividend | - Last Split | 28 Apr 2017 IPO Date |
Overview
Zymeworks Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of novel biotherapeutics for the treatment of cancer. Established in 2003 and headquartered in Vancouver, Canada, the company leverages its expertise in the field to develop cutting-edge treatments aimed at improving patient outcomes. Zymeworks Inc. has established a strong network of strategic partnerships with leading pharmaceutical and biotechnology companies, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb Company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Moreover, Zymeworks maintains licensing and research collaborations with LEO Pharma A/S and Iconic Therapeutics, Inc., focusing on the research, development, and commercialization of bispecific antibodies. These partnerships and collaborations underpin the company's efforts to bring innovative cancer treatments from the laboratory to the clinic.
Products and Services
- Zanidatamab
- ZW49
A novel bispecific antibody, zanidatamab is at the forefront of Zymeworks Inc.'s pipeline, currently undergoing Phase 1 and Phase 2 clinical trials. This innovative therapy is designed to target biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer. Through its dual-targeting mechanism, zanidatamab aims to provide a new therapeutic option for patients battling these forms of cancer, offering hope for improved treatment outcomes.
ZW49 represents Zymeworks Inc.'s advancement in the targeted treatment of HER2-expressing tumors. This biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate is currently in Phase 1 clinical trial, focusing on patients with advanced or metastatic HER2-expressing tumors. By combining targeted therapy with a potent cytotoxic drug, ZW49 has the potential to effectively kill cancer cells while minimizing harm to normal tissues, thus presenting a promising therapeutic approach for individuals with HER2-positive cancers.
